

Dominican Republic

Tuberculosis profile

Population 2016

11 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.56 (0.24–1)	5.2 (2.3–9.5)
Mortality (HIV+TB only)	0.49 (0.35–0.64)	4.6 (3.3–6)
Incidence (includes HIV+TB)	6.4 (4.9–8.2)	60 (46–77)
Incidence (HIV+TB only)	1.5 (1.1–2)	14 (11–19)
Incidence (MDR/RR-TB)**	0.42 (0.3–0.55)	4 (2.9–5.1)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.37 (0.27–0.46)	2 (1.5–2.6)	2.4 (1.8–3)
Males	0.38 (0.28–0.48)	3.7 (2.7–4.6)	4 (3–5.1)
Total	0.75 (0.55–0.94)	5.7 (4.2–7.2)	6.4 (4.9–8.2)

TB case notifications, 2016

Total cases notified	4 476
Total new and relapse	4 235
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	88%
- % pulmonary	88%
- % bacteriologically confirmed among pulmonary	63%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	66% (52–87)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.17 (0.1–0.25)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	893	24%
- on antiretroviral therapy	376	42%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			290 (230–360)
Estimated % of TB cases with MDR/RR-TB	2.9% (1.4–4.5)	34% (28–41)	
% notified tested for rifampicin resistance	7%	36%	527
MDR/RR-TB cases tested for resistance to second-line drugs			98
Laboratory-confirmed cases		MDR/RR-TB: 107, XDR-TB: 3	
Patients started on treatment ****		MDR/RR-TB: 140, XDR-TB: 1	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	80%	4 468
Previously treated cases, excluding relapse, registered in 2015	63%	201
HIV-positive TB cases registered in 2015	65%	909
MDR/RR-TB cases started on second-line treatment in 2014	50%	100
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	20%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017

National TB budget (US\$ millions)	15
Funding source: 65% domestic, 19% international, 17% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically